← Leaderboards
Mark Jesus Magbanua
University Of California, San Francisco
$1,548,687
Attributed
$4,646,061
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,646,061 · 2
By mechanism
R01$4,646,061 · 2
Top collaborators
- Wen Li5 shared
- Laura J Van'T Veer5 shared
- Mahdokht Masaeli2 shared
- Jennifer M. Rosenbluth2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Mary Helen Barcellos-Hoff$12,888,180
- Wen Li$1,096,933
- Laura J Van't Veer$11,693,569
- Michael T McManus$36,428,993
- Susan Halabi$7,630,539
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorModalityMutationTreatment ResponsePredicting ResponseBreast Cancer PatientLiquid BiopsyMonitorPatient ResponseResponseDiagnosisBiological MarkersPerformancePatient-Focused OutcomesErbb2 GeneImproved OutcomeMalignant Breast NeoplasmDiagnostic BiomarkerDisease-Free SurvivalDistantCancer BurdenAdvanced DiseaseDrug EfficacyCompanion Diagnostics
Grant awards (7)
Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cells$676,075
R01 · FY2025 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,225
R01 · FY2025 · CA
Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cells$679,188
R01 · FY2024 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$636,712
R01 · FY2024 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,820
R01 · FY2023 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,818
R01 · FY2022 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,223
R01 · FY2021 · CA